Transine® Therapeutics focuses on developing and exploiting the ground-breaking SINEUP® technology. Funded by Takeda Ventures, Inc. and the Dementia Discovery Fund, we are established in the UK and have international connections and vision. Collaboration, ambition and innovation are at the core of our plans to derive the maximum value from the technology and deliver it to patients.
Pioneers in the field of genomics, Transine® founders, Professor Stefano Gustincich and Professor Piero Carninci, identified a new functional and naturally occurring type of long non-coding RNAs (lncRNAs). Deciphering their effect in regulating the neuronal gene, UCHL1, the founding teams discovered a new mechanism by which protein expression can be increased. They named the new class of lncRNA, SINE-UP as it contained an inverted SINEB2 element, the functional element key to UP-regulating translation (Carrieri et al., Nature. 2012;491(7424):454-457).
Critically, the academic teams went on to describe that synthetic SINEUPs® could be engineered to target chosen proteins and cellular pathways on demand. Exciting publications from an array of studies followed and provided proof-of-concept data in a variety of in vitro and in vivo models (Indrieri A. & al, Sci Rep. 2016 Jun 6; Bon C. & al, Nucleic Acids Res. 2019 Nov 18 Espinoza S. & al, Mol Ther. 2020).
The emerging set of unique SINEUPs® properties, such as their specificity, controlled increase of expression, versatility, size, and modular nature led to recognising their potential as a completely novel modality for the treatment of both genetic and non-genetic diseases. In 2020, Transine received significant seed funding from Takeda Ventures, Inc. and the Dementia Discovery Fund to set up its operations, develop the platform, build a pipeline of novel therapeutics across several disease areas and commercialise the technology broadly inside and outside the therapeutic fields.
Got a question or would like more information? We would be very happy to hear from you.